Received 0 Karma
Received 0 Karma
Received 0 Karma
Received 0 Karma
Received 0 Karma
Received 0 Karma

[TimAlerts] $CTIC : "Investigators also analyzed the phase III study based on the 32% of patients enrolled with baseline platelet counts of 100,000 or less. Outside of a clinical trial, these patients would be candidates for treatment with a lowered dose of Jakafi. Here, the pacritinib spleen response was 17% versus zero response for the best alternative therapy." meaning, they are better than INCYTE's Jakafi at treating the same disease. INCYTE is 19$B mkt cap co. Not a fan of their adverse events thou
Received 0 Karma
Received 0 Karma

[TimAlerts] $SYRX It's not 20$B contract, read well PR
Received 0 Karma

